Page 3 - Havah Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Havah therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Havah Therapeutics Today - Breaking & Trending Today

Clarus Therapeutics (NASDAQ:CRXT) Price Target Cut to $3.00 by Analysts at Truist Financial

Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its target price decreased by stock analysts at Truist Financial from $7.00 to $3.00 in a research report issued to clients and investors on Tuesday, The Fly reports. Truist Financial’s target price indicates a potential upside of 458.24% from the stock’s previous close. Other research analysts have also […] ....

United States , Schonfeld Strategic Advisors , Powell Investment Advisors , Clarus Therapeutics Company Profile Get Rating , Zacks Investment Research , Renaissance Technologies , Needham Company , Citadel Advisors , Clarus Therapeutics Holdings Inc , Clarus Therapeutics , Get Rating , Truist Financial , Investment Research , Strategic Advisors , Investment Advisors , Therapeutics Company Profile , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Nasdaq Crxt , Lower Price Target , Truist Financial Co ,

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) Receives $10.79 Consensus Price Target from Brokerages

Shares of Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT – Get Rating) have received a consensus recommendation of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the […] ....

United States , Schonfeld Strategic Advisors , Powell Investment Advisors , Zacks Investment Research , Needham Company , Citadel Advisors , Clarus Therapeutics Holdings Inc , Clarus Therapeutics Holdings , Get Rating , Clarus Therapeutics , Investment Research , Investment Advisors , Strategic Advisors , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Nasdaq Crxt ,

Analysts Expect Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) Will Post Earnings of -$0.86 Per Share

Analysts expect Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT – Get Rating) to announce ($0.86) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Clarus Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.13) and the highest estimate coming in at ($0.59). The business is […] ....

United States , Thomson Reuter , Schonfeld Strategic Advisors , Powell Investment Advisors , Clarus Therapeutics Company Profile Get Rating , Zacks Investment Research , Needham Company , Verition Fund Management , Clarus Therapeutics Holdings Inc , Clarus Therapeutics Holdings , Get Rating , Clarus Therapeutic , Clarus Therapeutics , Investment Research , Fund Management , Investment Advisors , Therapeutics Company Profile , Therapeutics Holdings , Havah Therapeutics , Royal Institution , Mcgill University , Nasdaq Crxt ,